On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Age, Sex, Timing of Treatment Response Predict Avascular Necrosis in Children with ALL

Avascular necrosis (AVN), a disorder resulting from a temporary or permanent loss of blood supply to the bone, is one of the most serious...

Ibrutinib Well Tolerated in Patients With Central Nervous System Lymphoma

CHICAGO--With few treatment options available for central nervous system lymphoma (CNSL), patients with recurrent/refractory disease typically have poor outcomes, with response rates ranging between...

From ASH Meeting on Hematologic Malignancies: How would you treat a patient with nodular...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

2014 ASH Annual Meeting: Late But Certainly Not Least…

This year’s six late-breaking abstracts feature innovative research in preventing bleeding risk, better prediction tools in Hodgkin lymphoma, and new approaches for high-risk, difficult-to-treat...

Mechanisms of Ibrutinib Resistance Varied in ABC DLBCL

Lymphoma cells may develop resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib using a variety of potentially druggable pathways, opening the door to...

Early Data Show EZH2 Inhibitor Active in Non-Hodgkin Lymphoma

The EZH2 inhibitor EPZ-6438 appears to be a well-tolerated drug and is showing early evidence of anti-lymphoma activity in patients with non-Hodgkin lymphoma of...

Potent Small-Molecule BCL6 Inhibitor Active against ABC-, GCB-DLBCL Cells

Researchers have identified a novel, potent, and specific BCL6 inhibitor that effectively inhibited tumor growth in vitro and in vivo in activated B-cell (ABC)...

ASH Meeting on Lymphoma Biology: Creating a Roadmap for Future Research

More than 350 lymphoma experts from around the world convened at the American Society of Hematology’s first Meeting on Lymphoma Biology to share cutting-edge...

2014 ASH Annual Meeting Program Preview: A Discussion with Program Co-Chairs

Now that the “ASH Dash” to submit abstracts is finished, we can look forward to taking advantage of everything this year’s annual meeting in...
Advertisement

Current Issue

April 2019, Volume 5, Issue 5

This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.